Market Intelligence, Clinical Progress, and High-Purity Reagents for Non-Opioid Analgesic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1B (Cav2.2, N-type calcium channel) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1B Extracellular Loop Recombinant Protein (Fc fusion or truncated): high purity (>95%), endotoxin <1 EU/µg, sequence verified. HEK293 expressed. | View CACNA1B Products |
| Gene Delivery | CACNA1B Lentivirus Premade Particles: full-length ORF for stable cell line generation. Native membrane topology preserved for patch-clamp/FLIPR. | View CACNA1B Products |
| Benchmark Ab/Peptide | Anti-CACNA1B Reference Monoclonal Antibody and ω-Conotoxin GVIA/MVIIA analog; positive controls for binding and blocking assays. | View CACNA1B Products |
| Validator | CACNA1B siRNA Set: for knockdown verification and specificity confirmation. | View CACNA1B Products |
| Related Target A | CACNA2D1 (Alpha-2-Delta-1): auxiliary subunit of voltage-gated calcium channels; synergistic pain modulation target. | View CACNA2D1 Products |
| Related Target B | SCN9A (Nav1.7): parallel nociception pathway; key for combination analgesic strategies. | View SCN9A Products |
| Off-Target Control A | CACNA1A (P/Q-type): critical for selectivity screening against related voltage-gated calcium channels. | View CACNA1A Products |
| Off-Target Control B | CACNA1C (L-type): cardiac safety counter-screen for cardiovascular liability assessment. | View CACNA1C Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional expression of multi-pass ion channel | Lentiviral delivery of full-length CACNA1B with optimized accessory subunits (α2δ-1/β3); HEK293/CHO stable lines for patch-clamp and calcium flux. |
| State-dependent drug binding (open vs. resting) | Stable cell lines compatible with automated patch clamp and calcium flux assays; high viability for kinetic studies. |
| Cross-species evaluation for preclinical translation | Human, Mouse, and Cynomolgus CACNA1B ortholog lentivirus and extracellular loop proteins available; >95% purity, sequence verified. |
| Cav channel family selectivity (Cav2.2 vs. Cav2.1, Cav1.2) | Homolog panel proteins and full-length lentivirus for CACNA1A, CACNA1C, CACNA1E available for parallel counter-screening. |
| Lack of positive controls in biologic screening | Clinical benchmark reference antibody and ω-conotoxin standard included for assay normalization. |
| False positives / off-target binding | Validated siRNA provided to confirm true target engagement via knockdown baselines. |
Live CACNA1B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for CACNA1B is a critical pivot point in non-opioid analgesia. Ziconotide (Prialt), a synthetic ω-conotoxin peptide, demonstrated clinical validity for severe chronic pain but requires intrathecal delivery, limiting its use. Current R&D is shifting toward orally bioavailable, peripherally restricted small molecules and biologics targeting extracellular loops that can achieve systemic delivery. Key trends include state-dependent binding kinetics to minimize cardiovascular liabilities, combination regimens with Nav1.7 or TRPV1 inhibitors, and monoclonal antibodies directed at N-type channel extracellular epitopes for peripheral neuropathy. The next wave emphasizes highly selective subtype inhibition (Cav2.2 over Cav2.1 and Cav1.x) to reduce CNS side effects and expand the therapeutic window.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-dependent blocker) | Merck, Eli Lilly (legacy), Biovitrum, specialty biotechs | Chronic Neuropathic Pain, Cancer Pain | Whole-cell patch clamp on stable CACNA1B cell lines; need functional channel expression for selectivity and kinetic profiling. |
| Peptide / Toxin | Jazz Pharmaceuticals (Ziconotide), conopeptide developers | Severe Refractory Pain (spinal infusion) | Calcium flux assay on full-length channel; lentivirus-stable lines for IC50 determination. |
| Monoclonal Antibody / Biologic | Emerging innovators, academic consortia | Peripheral Neuropathy, Osteoarthritis Pain | Binding assays using high-purity extracellular loop antigens; function-blocking assays with native conformation. |
Molecular Characteristics of CACNA1B
CACNA1B encodes the α1B subunit of N-type voltage-gated calcium channels (Cav2.2). It contains an EF-hand calcium-binding domain (UniProt Q00975) critical for calcium-dependent inactivation. Clinically relevant mutations include rs4422842 (dbSNP) associated with altered channel function, NEDNEH variant noted in neurodevelopmental disorders, and rs7873074 (dbSNP) linked to pain sensitivity phenotypes. Understanding these structural and genetic features is essential for designing selective modulators and interpreting functional assay data.